Track topics on Twitter Track topics that are important to you
Through the early-stage trial called DUET-3, Xencor will assess the safety and tolerability of XmAb23104 in an estimated 144 patients with selected advanced solid tumors. The participants will
The post Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors appeared first on Pharmaceutical Business review.
Original Article: Xencor begins phase 1 trial of XmAb23104 in advanced solid tumorsNEXT ARTICLE